Skip to main content
. 2021 Sep 23;22(5):807. doi: 10.3892/ol.2021.13068

Figure 2.

Figure 2.

Effect of CRET and/or sorafenib treatment on the expression of the proliferation markers, PCNA and Ki67. (A) Western blotting of PCNA expression after treatment with CRET alone (4 or 24 h of intermittent exposure + 24 h post-exposure), sorafenib alone (4 or 48 h) or in combination. Data are presented as the ratio of PCNA to β-actin (PCNA/β-actin). All values represent the mean ± SEM of ≥3 experimental replicates. *P<0.05. (B) Representative western blots using β-actin as the loading control. (C) Immunofluorescence of Ki67 expression. Cells were treated with CRET alone (24 h + 24 h post-exposure), sorafenib alone (48 h) or in combination. *P<0.05, **P<0.01 and ***P<0.001. Data were statistically analyzed using One-way ANOVA followed by Bonferroni post-hoc test. (D) Representative images of immunofluorescence for Ki67. Green represents Ki67-positive cells stained with anti-Ki67 antibody and Alexa Fluor® 488. Blue represents nuclei stained with DAPI. Scale bar, 50 µm; same scale in all micrographs. CRET, capacitive-resistive electrothermal therapies; PCNA, proliferating cell nuclear antigen; Sorf, sorafenib; C, control.